Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) successfully completed the pre-IND (Investigational New Drug) meeting process with the U.S. Food and Drug Administration (FDA) for SP-3164 in hematological cancers and solid tumors.
The company is planning to submit an IND application in 2023, following the pre-IND meeting process, obtained valuable FDA input that provided clarity on preclinical, clinical, and other regulatory matters.
